AAAAAA

   
Results: 1-22 |
Results: 22

Authors: Vahteristo, P Syrjakoski, K Eerola, H Kainu, T Holli, K Blomqvist, C Kallioniemi, OP Nevanlinna, H
Citation: P. Vahteristo et al., Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselectedFinnish breast cancer patients - Response, J NAT CANC, 93(2), 2001, pp. 153-154

Authors: Barkardottir, RB Sarantaus, L Arason, A Vehmanen, P Bendahl, PO Kainu, T Syrjakoski, K Krahe, R Huusko, P Pyrhonen, S Holli, K Kallioniemi, OP Egilsson, V Kere, J Nevanlinna, H
Citation: Rb. Barkardottir et al., Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families, EUR J HUM G, 9(10), 2001, pp. 773-779

Authors: Jukkola, A Bloigu, R Soini, Y Savolainen, ER Holli, K Blanco, G
Citation: A. Jukkola et al., c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease, EUR J CANC, 37(3), 2001, pp. 347-354

Authors: Paakkonen, K Sauramo, S Sarantaus, L Vahteristo, P Hartikainen, A Vehmanen, P Ignatius, J Ollikainen, V Kaariainen, H Vauramo, E Nevanlinna, H Krahe, R Holli, K Kere, J
Citation: K. Paakkonen et al., Involvement of BRCA1 and BRCA2 in breast cancer in a Western Finnish sub-population, GENET EPID, 20(2), 2001, pp. 239-246

Authors: Lundin, J Lundin, M Holli, K Kataja, V Elomaa, L Pylkkanen, L Turpeenniemi-Hujanen, T Joensuu, H
Citation: J. Lundin et al., Omission of histologic grading from clinical decision making may result inoveruse of adjuvant therapies in breast cancer: Results from a nationwide study, J CL ONCOL, 19(1), 2001, pp. 28-36

Authors: Jukkola, A Bloigu, R Holli, K Joensuu, H Valavaara, R Risteli, J Blanco, G
Citation: A. Jukkola et al., Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer, ANTICANC R, 21(4B), 2001, pp. 2873-2876

Authors: Holli, K Saaristo, R Isola, J Joensuu, H Hakama, M
Citation: K. Holli et al., Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study, BR J CANC, 84(2), 2001, pp. 164-169

Authors: Syrjakoski, K Vahteristo, P Eerola, H Tamminen, A Kivinummi, K Sarantaus, L Holli, K Blomqvist, C Kallioniemi, OP Kainu, T Nevanlinna, H
Citation: K. Syrjakoski et al., Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients, J NAT CANC, 92(18), 2000, pp. 1529-1531

Authors: Sarantaus, L Huusko, P Eerola, H Launonen, V Vehmanen, P Rapakko, K Gillanders, E Syrjakoski, K Kainu, T Vahteristo, P Krahe, R Paakkonen, K Hartikainen, J Blomqvist, C Lopponen, T Holli, K Ryynanen, M Butzow, R Borg, A Arver, BW Holmberg, E Mannermaa, A Kere, J Kallioniemi, OP Winqvist, R Nevanlinna, H
Citation: L. Sarantaus et al., Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland, EUR J HUM G, 8(10), 2000, pp. 757-763

Authors: Maenpaa, J Holli, K Pasanen, T
Citation: J. Maenpaa et al., Toremifene: where do we stand?, EUR J CANC, 36, 2000, pp. S61-S62

Authors: Hietanen, P Aro, AR Holli, K Absetz, P
Citation: P. Hietanen et al., Information and communication in the context of a clinical trial, EUR J CANC, 36(16), 2000, pp. 2096-2104

Authors: Holli, K Valavaara, R Blanco, G Kataja, V Hietanen, P Flander, M Pukkala, E Joensuu, H
Citation: K. Holli et al., Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer, J CL ONCOL, 18(20), 2000, pp. 3487-3494

Authors: Joensuu, H Holli, K Oksanen, H Valavaara, R
Citation: H. Joensuu et al., Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer, BREAST CANC, 63(3), 2000, pp. 225-234

Authors: Kainu, T Juo, SHH Desper, R Schaffer, AA Gillanders, E Rozenblum, E Freas-Lutz, D Weaver, D Stephan, D Bailey-Wilson, J Kallioniemi, OP Tirkkonen, M Syrjakoski, K Kuukasjarvi, T Koivisto, P Karhu, R Holli, K Arason, A Johannesdottir, G Bergthorsson, JT Johannsdottir, H Egilsson, V Barkardottir, RB Johannsson, O Haraldsson, K Sandberg, T Holmberg, E Gronberg, H Olsson, H Borg, A Vehmanen, P Eerola, H Heikkila, P Pyrhonen, S Nevanlinna, H
Citation: T. Kainu et al., Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus, P NAS US, 97(17), 2000, pp. 9603-9608

Authors: Jarvinen, TAH Pelto-Huikko, M Holli, K Isola, J
Citation: Tah. Jarvinen et al., Estrogen receptor beta is coexpressed with ER alpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer, AM J PATH, 156(1), 2000, pp. 29-35

Authors: Holli, K Isola, J Hakama, M
Citation: K. Holli et al., Changes in importance of items in the social and personal life of breast cancer patients over time, BREAST, 8(3), 1999, pp. 155-156

Authors: Saarenmaa, I Salminen, T Geiger, U Holli, K Isola, J Karkkainen, A Pakkanen, J Piironen, A Salo, A Hakama, M
Citation: I. Saarenmaa et al., The visibility of cancer on earlier mammograms in a population-based screening programme, EUR J CANC, 35(7), 1999, pp. 1118-1122

Authors: Ylitalo, P Holli, K Monkkonen, J Elo, HA Juhakoski, A Liukko-Sipi, S Ylitalo, R
Citation: P. Ylitalo et al., Comparison of pharmacokinetics of clodronate after single and repeated doses, INT J CL PH, 37(6), 1999, pp. 294-300

Authors: Holli, K Laippala, P Ojala, A Pitkanen, M
Citation: K. Holli et al., Quality control in health care: An experiment in radiotherapy planning forbreast cancer patients after mastectomy, INT J RAD O, 44(4), 1999, pp. 827-833

Authors: Holli, K Visakorpi, T Hakama, M
Citation: K. Holli et al., Smoking and survival from lung cancer, ACTA ONCOL, 38(8), 1999, pp. 989-992

Authors: Holli, K
Citation: K. Holli, Hereditary breast cancer, ACTA ONCOL, 38, 1999, pp. 29-32

Authors: Joensuu, H Holli, K Heikkinen, M Suonio, E Aro, AR Hietanen, P Huovinen, R
Citation: H. Joensuu et al., Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial, J CL ONCOL, 16(12), 1998, pp. 3720-3730
Risultati: 1-22 |